The quality of life of adults with attention deficit hyperactivity disorder: A systematic review

Innovations in Clinical Neuroscience

Volumn 9, Issue 5-6, 2012, Pages 10-21

  Agarwal, Rashi ^a   Goldenberg, Matthew ^b   Perry, Robert ^c   Ishak, Waguih William ^c  

^a BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^b BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adult attention deficit hyperactivity disorder; Quality of life

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CLONIDINE; GUANFACINE; PLACEBO; POZANICLINE;

ADHD IMPACT MODULE ADULT; ADULT ADHD QUALITY OF LIFE; ATTENTION DEFICIT DISORDER; CLINICAL RESEARCH; DRUG EFFICACY; DSM-IV-TR; HUMAN; ICD-11; OUTCOME ASSESSMENT; PSYCHOMETRY; QUALITY OF LIFE; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE SHORT FORM; REVIEW; SCORING SYSTEM; SHORT FORM 36; SLEEP QUALITY; SOCIAL ADAPTATION; SOCIAL INTERACTION; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION QUALITY OF LIFE;

EID: 84867074881     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Brod M, Johnston J, Able S, Swindle R. Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res. 2006 Feb;15(1):117-129.
2. Adler LA, Sutton VK, Moore RJ. Quality of life assessment in adult patients with attentiondeficit/hyperactivity disorder treated with atomoxetine. J Clin Psychopharmacol. 2006;26:648-652.
3. Kessler RC, Green JG, Adler LA. Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic Scale. Arch Gen Psychiatry. 2010;67:1168-1178.
4. Rosler M, Casas M, Konofal E, Buitelaar J. Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry. 2010;11(5):684-698.
5. Sentissi O, Navarro JC, De Oliveira H. Bipolar disorder and quality of life: impact of ADHD and substance abuse in euthymic patients. Psychiatry Res. 2008;30:36-42.
6. Schmidt S, Petermann F. Developmental psychopathology: Attention deficit hyperactivity disorder (ADHD). BMC Psychiatry. 2009;17:58.
7. Kessler RC, Adler LA, Barkley R. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biologic Psychiatry. 2005;57:1442-1451.
8. Ribases M, Ramos-Quiroga JA, Sanchez-Mora C. Contribution of LPHN3 to the genetic susceptibility to ADHD in adulthood: a replication study. Genes Brain Behav. 2011;10(2):149-157.
9. Hsiung PC, Fang CT, Chang YY, et al. Comparison of WHO QOL-bREF and SF-36 in patients with HIV infection. Qual Life Res. 2005;14(1):141-150.
10. Huang IC, Wu AW, Frangakis C. Do the SF-36 and WHO QOL-BREF measure the same constructs? evidence from the Taiwan population. Qual Life Res. 2006 Feb;15(1):15-24.
11. Mick E, Faraone SV, Spencer T, Zhhang HF, Biederman J. Assessing the validity of the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form in adults with ADHD. Journal of Attention Disorders. 2008; 11: 504-509.
12. Matza LS, Johnston JA, Faries. Responsiveness of adult attentiondeficit/ hyperactivity disorder quality of life scale (AAQoL). Qual Life Res. 2007;16:1511-1520.
13. Matza LS, Van Brunt DL, Cates C, Murray LT. Test-retest reliability of two patient-report measures for use in adults with ADHD. J Atten Disord. 2011 Oct;15(7):557-563.
14. Landgraf JM. Monitoring quality of life in adults with ADHD: reliability and validity of a new measure. J Atten Disord. 2007;11:351-362.
15. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407-415.
16. Chao CY, Gau SS, Mao. Relationship of attention-deficithyperactivity disorder symptoms, depressive/ anxiety symptoms, and life quality in young men. Psychiatry Clin Neurosci. 2008;62:421-426.
17. Gudjonsson GH, Sigurdsson JF, Eyjolfsdottir GA, et al. The relationship between satisfaction with life, ADHD symptoms, and associated problems among university students. J Atten Disord. 2009;12(6):507-515.
18. Rimmerman A, Yurkevich O, Birger M, Araten-Bergman T. Quality of life in men and women with borderline intelligence and attention deficit disorders living in community residencies: a comparative study. J Atten Disord. 2005;9:435-443.
19. Rimmerman A, Yurkevich O, Birger M. Quality of life of Israeli adults with borderline intelligence quotient and attentiondeficit/ hyperactivity disorder. Int J Rehab Res. 2007;30:55-60.
20. Weiss MD, Gibbins C, Goodman DW. Moderators and mediators of symptoms and quality of life outcomes in an open-label study of adults treated for attentiondeficit/ hyperactivity disorder. J Clin Psychiatry. 2010;71(4):381-390.
21. Adler LA, Spencer T, Brown TE. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009;29;44-50.
22. Matza LS, Stoeckl MN, Shorr JM, Johnston JA. Impact of atomoxetine on health-related quality of life and functional status in patients with ADHD. Expert Rev Pharmacoecon Outcomes Res. 2006;6(4):379-390.
23. Adler LA, Spencer TJ, Levine LR. Functional outcomes in the treatment of adults with ADHD. J Atten Dis. 2008;11:720-727.
24. Safren SA, Sprich SE, Cooper- Vince C, et al. Life impairments in adults with medication-treated ADHD. J Atten Dis. 2010;13:524-531.
25. Adler LA, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009;26(3):212-221.
26. Spencer TJ, Landgraf JM, Adler LA. Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69:1766-1775.
27. Spencer TJ, Adler LA, Weisler RH, Youcha SH. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. J Clin Psychiatry. 2008;69:1437-1448.
28. Brown TE, Landgraf JM. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, doubleblind, randomized, placebocontrolled trials in ADHD. Postgrad Med. 2010;122:42-51.
29. Goodman DW, Ginsberg L, Weisler R. An interim analysis of the quality of life, effectiveness, safety, and tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10:26-34.
30. Boonstra AM, Kooij JJ, Oosterlaan J. Hyperactive night and day? Actigraphy studies in adult ADHD: a baseline comparison and the effect of methylphenidate. Sleep. 2007;30:433-442.
31. Kooij JJ, Middelkoop HA, van Gils K, Buitelaar JK. The effect of stimulants on nocturnal motor activity and sleep quality on adults with ADHD: an open label case control study. J Clin Psychiatry. 2001;62: 952-956.
32. Adler LA, Goodman D, Weisler R. Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder. Behav Brain Funct. 2009;5:34.
33. Skevington SM, Lotfy M, O'Connell KA; WHOQOL Group. The World Health Organizations WHOQOLBREF quality of life assessment: psychometric properties and results of the international field trial: a report from the WHOQOL Group. Qual Life Res. 2004 Mar;13(2):299-310.
34. Carpentier PJ, van Gogh MT, Knapen LJ. Influence of attention deficit hyperactivity disorder and conduct disorder on opioid dependence severity and psychiatric comorbidity in chronic methadone-maintained patients. Eur Addict Res. 2011;17(1):10-20.
35. Goksøyr PK, Nøttestad JA. The burden of untreated ADHD among adults: the role of stimulant medication. Addictive Behaviors. 2007; 33: 342-346.
36. Ishak WW, Greenberg JM, Saah T, et al. Development and validation of the Individual Burden of Illness Index for Major Depressive Disorder (IBI-D). Adm Policy Ment Health. 2011 Oct 4. [Epub ahead of print].
37. Schalock RL, Keith KD. Quality of Life Questionnaire Manual. Worthington, OH: IDS Publishing Corporation; 1993.
38. Grenwald-Mayes G. Relationship between current quality of life and family of origin dynamics for college students with attention deficit hyperactivity disorder. J Atten Disord. 2002;5(4):211-222.
39. Goksøyr PK, Nøttestad JA. The burden of untreated ADHD among adults: the role of stimulant medication. Addict Behav. 2008;33(2):342-346.